Loading...
Loading...
Morgan Stanley reiterates its Overweight rating and $36 target price on Oracle
ORCL as the company sees a myriad of catalysts in CY12.
Morgan Stanley says, “While we expect Q2 to be solid, our positive thesis on ORCL is about several CY12 drivers including a) a firm apps cycle converging with the Fusion Apps catalyst, b) an improving middleware & analytics story, c) hardware accelerating to 10%+ growth on Exa-family strength and d) margins expanding faster than people expect.”
ORCL closed at $29.87 per share on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in